Subject(s)
Adult , Middle Aged , Aged , Humans , Male , Female , Arthritis, Rheumatoid/drug therapy , Aspirin/adverse effects , Adrenal Cortex Hormones/adverse effects , /adverse effects , Gastric Mucosa/drug effects , Peptic Ulcer/chemically induced , Ranitidine/administration & dosage , Clinical Trials as Topic , Random Allocation , Prospective Studies , Peptic Ulcer/drug therapySubject(s)
Adult , Middle Aged , Humans , Male , Female , Adrenal Cortex Hormones/adverse effects , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Arthritis, Rheumatoid/drug therapy , Aspirin/adverse effects , Gastric Mucosa/drug effects , Clinical Trials as Topic , Peptic Ulcer/chemically induced , Peptic Ulcer/drug therapy , Prospective Studies , Random Allocation , Ranitidine/administration & dosageABSTRACT
In a group of 70 patients of both sexes been treated with antiinflammatory drugs, affected by Rheumatoid Arthritis in activity, we have found the presence of lesions, erosions and gastroduodenal ulcers in 40% by endoscopic examination (26% erosions and 14% ulcers), without any relation with clinical symptoms. Those patients who received larger doses than 30mgr./kg./day of AAS suffered most frequently lesions (43.8%). These 28 patients with lesions have been studied prospectively in a double blind method, and treated twice a day with 150 mgs. doses of Ranitidine or Placebo, throughout a period of 5 weeks without discontinuing the treatment with anti-inflammatories (AAS, Indomethacin, steroids). At the end of the trial those patients who failed in healing their lesions were treated with Ranitidine in the same doses for another period of 5 weeks. The treatment with Ranitidine in doses of 300 mgr/day has resulted curative of the gastroduodenal lesions, although maintaining the aggressive drugs, in the 87% of the patients. We have observed that the treatment with Placebo is less effective and that difference has high statistical significance (p 0.005).
Subject(s)
Adrenal Cortex Hormones/adverse effects , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Arthritis, Rheumatoid/drug therapy , Aspirin/adverse effects , Gastric Mucosa/drug effects , Adult , Aged , Clinical Trials as Topic , Female , Humans , Male , Middle Aged , Peptic Ulcer/chemically induced , Peptic Ulcer/drug therapy , Prospective Studies , Random Allocation , Ranitidine/administration & dosageABSTRACT
In a group of 70 patients of both sexes been treated with antiinflammatory drugs, affected by Rheumatoid Arthritis in activity, we have found the presence of lesions, erosions and gastroduodenal ulcers in 40
by endoscopic examination (26
erosions and 14
ulcers), without any relation with clinical symptoms. Those patients who received larger doses than 30mgr./kg./day of AAS suffered most frequently lesions (43.8
). These 28 patients with lesions have been studied prospectively in a double blind method, and treated twice a day with 150 mgs. doses of Ranitidine or Placebo, throughout a period of 5 weeks without discontinuing the treatment with anti-inflammatories (AAS, Indomethacin, steroids). At the end of the trial those patients who failed in healing their lesions were treated with Ranitidine in the same doses for another period of 5 weeks. The treatment with Ranitidine in doses of 300 mgr/day has resulted curative of the gastroduodenal lesions, although maintaining the aggressive drugs, in the 87
of the patients. We have observed that the treatment with Placebo is less effective and that difference has high statistical significance (p 0.005).
ABSTRACT
Misoprostol (Mi, a double blind study in the treatment of active duodenal ulcer (DU). The purpose of the paper was to evaluate the effect of Mi vs. Placebo (Pl) without antacids, assessing at the same time side effects and histological alterations. Thirty five patients with active DU diagnosed by endoscopy and photography (performed on days, 0, 14 and 28) were studied. They received 4 doses/day of Mi 100 mcg, or Pl double blind. In each control, biochemical studies in blood and urine were performed. Acetaminophen, 500 mg was the only analgesic allowed. Six patients were excluded. Of the remaining 29 patients, 15 received Mi and 14 Pl. There was no difference in healing at the 14 day stage. At the 28 day stage there was complete healing of the ulcer in 66.6%, and reduction of the ulcer diameter of 89% those who received Mi. The healing rate was 28.5% and reduction of the ulcer diameter of 31% on those patients who received placebo. There were no biochemical alterations or side effects. There was no significative difference between biopsies taken from pylorus and antrum. The consumption of acetaminophen was similar to both groups. It is concluded that Mi has a healing effect similar to H2 blocking agents, accelerating the healing of active DU, without side effects and biochemical changes.
Subject(s)
Alprostadil/analogs & derivatives , Anti-Ulcer Agents/therapeutic use , Duodenal Ulcer/drug therapy , Acetaminophen/administration & dosage , Adolescent , Adult , Age Factors , Aged , Alprostadil/pharmacology , Alprostadil/therapeutic use , Clinical Trials as Topic , Double-Blind Method , Duodenal Ulcer/pathology , Female , Gastric Acid/metabolism , Humans , Male , Middle Aged , Misoprostol , Sex Factors , Wound Healing/drug effectsABSTRACT
Estudio doble ciego con misoprostol (Mi) en el tratamiento de la Ulcera Duodenal (UD) activa. Este trabajo fue realizado para valorar el efecto curativo del Mi (análogo metil ester sintético de la PGE1, vs. placebo (PI) sin antiácidos, observando, efectos adversos y alteraciones histológicas. Se estudiaron 35 pacientes con UD activa diagnosticada por endoscopía y control fotográfico realizado los días 0, 14 y 28, recibiendo 4 dosis/día de Mi 100 mcg cada uno o PI con método doble ciego. En cada control se realizó estudio bioquímico sanguíneo y urinario, permitiéndose solamente la ingesta de comprimidos de Acetoaminofen de 500 mg como único analgésico. Se valoraron los resultados obtenidos en 29 pacientes, pues 6 fueron excluidos; 15 recibieron Mi y 14 PI. No se demostró diferencia en la cicatrización a los 14 días, mientras que a los 28 días observó curación completa en el 66.6% de los que recibieron Mi con reducción del diámetro de la UD de un 89% y los que recibieron placebo, curación en un 28,5% con reducción del diámetro ulceroso de un 31%. No se observó alteraciones bioquímicas ni efectos adversos. Las biopsias realizadas en zona pilórica y antral los días 0, 14 y 28 no mostraron diferencias morfológicas ni histológicas significativas. El consumo de Acetoaminofen fue similar. Se concluye que el Mi mostró un efecto curativo similar al obtenido con los bloqueantes receptores H2, acelerando la cicatrización de la UD sin efectos colaterales ni modificaciones bioquímicas (AU)
Subject(s)
Adolescent , Adult , Middle Aged , Aged , Humans , Male , Female , Prostaglandins E, Synthetic/therapeutic use , Duodenal Ulcer/drug therapy , Acetaminophen/administration & dosage , Wound Healing/drug effects , Clinical Trials as Topic , Age Factors , Sex Factors , Double-Blind MethodABSTRACT
Misoprostol (Mi, a double blind study in the treatment of active duodenal ulcer (DU). The purpose of the paper was to evaluate the effect of Mi vs. Placebo (Pl) without antacids, assessing at the same time side effects and histological alterations. Thirty five patients with active DU diagnosed by endoscopy and photography (performed on days, 0, 14 and 28) were studied. They received 4 doses/day of Mi 100 mcg, or Pl double blind. In each control, biochemical studies in blood and urine were performed. Acetaminophen, 500 mg was the only analgesic allowed. Six patients were excluded. Of the remaining 29 patients, 15 received Mi and 14 Pl. There was no difference in healing at the 14 day stage. At the 28 day stage there was complete healing of the ulcer in 66.6
, and reduction of the ulcer diameter of 89
those who received Mi. The healing rate was 28.5
and reduction of the ulcer diameter of 31
on those patients who received placebo. There were no biochemical alterations or side effects. There was no significative difference between biopsies taken from pylorus and antrum. The consumption of acetaminophen was similar to both groups. It is concluded that Mi has a healing effect similar to H2 blocking agents, accelerating the healing of active DU, without side effects and biochemical changes.
ABSTRACT
Estudio doble ciego con misoprostol (Mi) en el tratamiento de la Ulcera Duodenal (UD) activa. Este trabajo fue realizado para valorar el efecto curativo del Mi (análogo metil ester sintético de la PGE1, vs. placebo (PI) sin antiácidos, observando, efectos adversos y alteraciones histológicas. Se estudiaron 35 pacientes con UD activa diagnosticada por endoscopía y control fotográfico realizado los días 0, 14 y 28, recibiendo 4 dosis/día de Mi 100 mcg cada uno o PI con método doble ciego. En cada control se realizó estudio bioquímico sanguíneo y urinario, permitiéndose solamente la ingesta de comprimidos de Acetoaminofen de 500 mg como único analgésico. Se valoraron los resultados obtenidos en 29 pacientes, pues 6 fueron excluidos; 15 recibieron Mi y 14 PI. No se demostró diferencia en la cicatrización a los 14 días, mientras que a los 28 días observó curación completa en el 66.6% de los que recibieron Mi con reducción del diámetro de la UD de un 89% y los que recibieron placebo, curación en un 28,5% con reducción del diámetro ulceroso de un 31%. No se observó alteraciones bioquímicas ni efectos adversos. Las biopsias realizadas en zona pilórica y antral los días 0, 14 y 28 no mostraron diferencias morfológicas ni histológicas significativas. El consumo de Acetoaminofen fue similar. Se concluye que el Mi mostró un efecto curativo similar al obtenido con los bloqueantes receptores H2, acelerando la cicatrización de la UD sin efectos colaterales ni modificaciones bioquímicas
Subject(s)
Adolescent , Adult , Middle Aged , Humans , Male , Female , Prostaglandins E, Synthetic/therapeutic use , Duodenal Ulcer/drug therapy , Acetaminophen/administration & dosage , Age Factors , Wound Healing/drug effects , Clinical Trials as Topic , Double-Blind Method , Sex FactorsSubject(s)
Cimetidine/pharmacology , Guanidines/pharmacology , Animals , Cats , Chemical Phenomena , Chemistry , Cimetidine/metabolism , Cimetidine/toxicity , Dogs , Drug Synergism , Duodenal Ulcer/drug therapy , Esophagogastric Junction/drug effects , Gastric Juice/drug effects , Gastric Juice/metabolism , Gastrins/blood , Gastrointestinal Hemorrhage/drug therapy , Guinea Pigs , Haplorhini , Heart/drug effects , Humans , Immunity/drug effects , In Vitro Techniques , Intrinsic Factor/metabolism , Mice , Pancreas/drug effects , Parasympatholytics/pharmacology , Peptic Ulcer/drug therapy , Rats , Receptors, Histamine H1/pharmacology , Receptors, Histamine H2/pharmacologyABSTRACT
Thirty six patients with active duodenal ulcers were studied in this double blind work. 19 received placebo and 17 Cimetidine: 1 gr./day. The endoscopic control after 21 days, showed healing in 81,2% of the cases treated with Cimetidine and in 22,2% of those with placebo. After 42 days of continous treatment with Cimetidine the healing of duodenal ulcers was 82,3% against 50% with placebo; the difference being highly statestically significant; p less than 0.01. The symptoms improved with Cimetidine revealing less diurnal and nocturnal pain complete disappearance of nausea and vomit and a significant decreased ingestion of alkali tablets.
Subject(s)
Cimetidine/therapeutic use , Duodenal Ulcer/drug therapy , Guanidines/therapeutic use , Adolescent , Adult , Cimetidine/administration & dosage , Clinical Trials as Topic , Creatinine/metabolism , Double-Blind Method , Duodenal Ulcer/diagnostic imaging , Endoscopy , Gastric Juice/metabolism , Humans , Middle Aged , Placebos/therapeutic use , Radiography , Transaminases/metabolismABSTRACT
The results of the study of 37 patients with gastric polyps are analysed. The different methods show as most frequent findings; solitary polyps, 73%; sessile, 60%; of antral localization, 70%; smaller than 2 cm., 78%; with chronic gastritis histology, 50%; and with hypochlorhydria, 77% (achlorhydria, 62%). The incidence of malignancy was of 10%. The fost frequent concomitant pathologies were cholecystopathy (33%) and diabetes mellitus (30%). Abdominal pain, anaemia and digestive tube bleeding were the most frequent findings, with an incidence of 40%. An attempt is made to establish diagnostic and therapeutics standards and follow up criteria are presented.
Subject(s)
Polyps , Stomach Neoplasms , Adenoma/diagnosis , Adult , Aged , Diagnosis, Differential , Female , Gastric Juice/metabolism , Gastroscopy , Humans , Male , Middle Aged , Polyps/classification , Polyps/complications , Polyps/diagnosis , Polyps/epidemiology , Polyps/pathology , Stomach Neoplasms/complications , Stomach Neoplasms/diagnosis , Stomach Neoplasms/epidemiology , Stomach Neoplasms/pathology , Stomach Neoplasms/physiopathologySubject(s)
Gastric Mucosa/metabolism , Prostaglandins/physiology , Animals , Biliary Tract Diseases/drug therapy , Chemistry , Cyclic AMP/physiology , Gastric Juice/drug effects , Gastric Juice/metabolism , Gastrins/metabolism , History, 20th Century , Humans , Peptic Ulcer/drug therapy , Prostaglandins/classification , Prostaglandins/history , Prostaglandins/therapeutic use , Prostaglandins E/pharmacology , Prostaglandins E, Synthetic/pharmacologyABSTRACT
Thirty six patients with active duodenal ulcers were studied in this double blind work. 19 received placebo and 17 Cimetidine: 1 gr./day. The endoscopic control after 21 days, showed healing in 81,2
of the cases treated with Cimetidine and in 22,2
of those with placebo. After 42 days of continous treatment with Cimetidine the healing of duodenal ulcers was 82,3
against 50
with placebo; the difference being highly statestically significant; p less than 0.01. The symptoms improved with Cimetidine revealing less diurnal and nocturnal pain complete disappearance of nausea and vomit and a significant decreased ingestion of alkali tablets.
ABSTRACT
The results of the study of 37 patients with gastric polyps are analysed. The different methods show as most frequent findings; solitary polyps, 73
; sessile, 60
; of antral localization, 70
; smaller than 2 cm., 78
; with chronic gastritis histology, 50
; and with hypochlorhydria, 77
(achlorhydria, 62
). The incidence of malignancy was of 10
. The fost frequent concomitant pathologies were cholecystopathy (33
) and diabetes mellitus (30
). Abdominal pain, anaemia and digestive tube bleeding were the most frequent findings, with an incidence of 40
. An attempt is made to establish diagnostic and therapeutics standards and follow up criteria are presented.
ABSTRACT
Thirty six patients with active duodenal ulcers were studied in this double blind work. 19 received placebo and 17 Cimetidine: 1 gr./day. The endoscopic control after 21 days, showed healing in 81,2
of the cases treated with Cimetidine and in 22,2
of those with placebo. After 42 days of continous treatment with Cimetidine the healing of duodenal ulcers was 82,3
with placebo; the difference being highly statestically significant; p less than 0.01. The symptoms improved with Cimetidine revealing less diurnal and nocturnal pain complete disappearance of nausea and vomit and a significant decreased ingestion of alkali tablets.
